Guerbet

Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer

17 Jul 2023 10:00:19 By Nasdaq GlobeNewswire

Guerbet: Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development

10 Jul 2023 08:48:16 By Nasdaq GlobeNewswire

Guerbet: Changes in Guerbet's Board of Directors

26 May 2023 08:29:04 By Nasdaq GlobeNewswire

Guerbet: Q1 2023 Revenue

20 Apr 2023 08:49:25 By Nasdaq GlobeNewswire

Guerbet: 2022 annual results

22 Mar 2023 09:45:58 By Nasdaq GlobeNewswire

Guerbet: 2022 revenue

09 Feb 2023 08:46:34 By Nasdaq GlobeNewswire

Guerbet: 2023 Strategic Priorities

16 Jan 2023 09:40:42 By Nasdaq GlobeNewswire

Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions

11 Jan 2023 10:46:47 By Nasdaq GlobeNewswire

Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects

03 Nov 2022 10:04:18 By Nasdaq GlobeNewswire

Guerbet: Revenue at September 30, 2022

20 Oct 2022 08:45:00 By Nasdaq GlobeNewswire

Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer

26 Sep 2022 09:00:00 By Nasdaq GlobeNewswire

Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)

21 Sep 2022 10:00:00 By Nasdaq GlobeNewswire

Guerbet: 2022 half-year results

21 Sep 2022 08:45:00 By Nasdaq GlobeNewswire

Guerbet: Revenue at June 30, 2022

21 Jul 2022 08:45:00 By Nasdaq GlobeNewswire

Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol

12 Jun 2022 23:30:00 By Nasdaq GlobeNewswire

Guerbet: Q1 2022 revenue

21 Apr 2022 08:45:00 By Nasdaq GlobeNewswire

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel

05 Apr 2022 23:30:00 By Nasdaq GlobeNewswire

Guerbet - Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA - Priority Review granted by US-FDA March 28, 2022

29 Mar 2022 09:05:55 By Nasdaq GlobeNewswire

Guerbet: 2021 annual results

23 Mar 2022 09:45:00 By Nasdaq GlobeNewswire

Guerbet: Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization

07 Mar 2022 09:00:48 By Nasdaq GlobeNewswire